Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-ALK-1 monoclonal antibody GT90001

A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-ALK-1 monoclonal antibody GT90001 targets and binds to ALK-1, and prevents ALK-1 activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents ALK-1-mediated endothelial cell signaling and the activation of transforming growth factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1 is a type I cell surface receptor and plays a key role in angiogenesis.
Synonym:anti-activin receptor-like kinase-1 monoclonal antibody GT90001
Code name:GT9 0001
GT9-0001
GT90001
Search NCI's Drug Dictionary